Ireland
--:--IST
Recruiting Phase 1/2

Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients

NCT06490731 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 1/2
Started
2026-04-01
Last updated
2026-05-07

Condition(s) studied

Haemodynamic Rebound

Investigational drug(s) / intervention(s)

Dexmedetomidine →Ketamine →

Dexmedetomidine: Patients will receive dexmedetomidine

Ketamine: patients Will receive ketamine

Study summary

Inflammatory response and hemodynamic response in patients with intraabdominal sepsis and Effects of Dexmedetomidine versus ketamine on it .

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * • Adult patients admitted to ICU after ileus surgery (perforated viscus, infarcted bowel, strangulated hernia, anastomotic leakage, diverticulitis, and intestinal obstruction), and who will be expected to require postoperative sedation and ventilation. * Abdominal sepsis was determined as organ dysfunction with a substantial change in overall SOFA score (2) ≥ 2 points because of intra-abdominal sepsis. Exclusion Criteria: * • Known allergy to ketamine, dexmedetomidine, * Confirmed pregnancy, * Heart failure (class 3 or 4 of the New York Heart Association), * Renal failure (RIFLE classification), * Liver failure (manifested by serum total protein concentration \<3 g/dl and total bilirubin \>5 mg/dl) * Known or suspected brain death. * Patients who receive neuromuscular blockers during the first 48 hours of ICU admission will also be excluded.

Primary outcome measure(s)

  • blood pressure — 48 hours
    Effect of the study drugs as sedative agents on blood pressure in mechanically ventilated septic patients after abdominal exploration for intestinal surgery.

Trial sites (1)

FacilityCityRegionStatus
asyut University Asyut Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06490731 on ClinicalTrials.gov ↗ ← All trials in Egypt